Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neuroleptics and Anti-Epileptics for Agitated Delirium in Advanced Cancer
NCT05431595Phase 3Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2022
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of haloperidol, Aminazin and valproic acid in delirium (4 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Frequency of breakthrough restlessness at 72 hours and Edmonton Symptom Assessment Scale Questionnaire at 1 year. Started Jul 2022; status: recruiting.
02
Drugs
haloperidolAminazinvalproic acid
03
Conditions
delirium
Beyond the preview
Go deeper on NCT05431595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05431595.